Table 2. Morbidity and mortality in the ‘control’ and the ‘prophylactic lamivudine’ groups.

	Control group		Prophylactic lamivudine group
	N	%	N	%	P-value
No. of patients	76		55
Overall morbidity
Incidences of hepatitis	25	33	5	9	0.001
Hepatitis attributable to HBV reactivation	16	21	1	2	0.001
Severity of hepatitis					0.001
Mild (HBV reactivation)	3 (2)	4	3 (0)	7
Moderate (HBV reactivation)	7 (1)	10	2 (1)	3
Severe (HBV reactivation)	15 (13)	19	0 (0)	0
HBV DNA at reactivation (mean, pg)	128 970		93 567		0.132
Disruptions of chemotherapy	11	14	2	3	0.04
Premature termination	2	3	0	0
Hepatitis due to HBV reactivation	2	3	0	0
Completion of chemotherapy with delay of >8 days	9	12	2	3
Hepatitis, all cases	9	12	2	3
Hepatitis due to HBV reactivation	5	7	0	0
Other causes	0	0	0	0
Overall mortality related to hepatitis B reactivation	0	0	0	0
Median no. of chemotherapy cycles received (range)	6.1 (1–9)		6.8 (4–8)		0.018

Abbreviation: HBV=Hepatitis B virus.